SCHEMBL25752940

SCHEMBL25752940

O=Cc1cc(OC(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 3/20 0.46
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
ALDH1A3 P47895 1/20 0.31
RPS6KA3 P51812 1/20 0.30
JAK3 P52333 1/20 0.30
SOD1 P00441 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18001998 0.87 DRD1 (0.46) DRD1ALDH1A1POLBL3MBTL1MEN1
SCHEMBL413618 0.83 DRD1 (0.57) DRD1ALDH1A1MEN1LMNAMAPT
SCHEMBL16961916 0.83 MEN1 (0.34) DRD1MEN1LMNAMAPTHTT
SCHEMBL16951066 0.83 MEN1 (0.37) DRD1MEN1LMNAMAPTHTT
SCHEMBL18002369 0.82 DRD1 (0.42) DRD1
SCHEMBL18002242 0.82 PTGS1 (0.50) DRD1ALDH1A1POLBL3MBTL1PPARA
SCHEMBL18002531 0.81 POLB (0.40) DRD1POLBMAPTIDO1SOD1
SCHEMBL18002380 0.81 NFE2L2 (0.47) DRD1ALDH1A1POLBL3MBTL1MEN1
SCHEMBL2600018 0.79 PTGS1 (0.46) ALDH1A1POLBL3MBTL1
SCHEMBL29490987 0.79 PTGS1 (0.46) ALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049806-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE CORP (JP) 2025-02-13 US disclosed
EP-4431098-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE Corporation (JP) 2024-09-18 EP disclosed
CN-115551846-B 1,4,5, 6-tetrahydropyrimidin-2-amine derivatives UBE株式会社 2024-03-08 CN disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed
EP-4151632-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE Corporation (JP) 2023-03-22 EP disclosed
CN-115551846-A 1,4,5,6-tetrahydropyrimidin-2-amine derivatives UBE株式会社 2022-12-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 DRD1 109/4885ALDH1A1 208/4885POLB 860/4885
US-20250049806-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME CYP21A2, HSD11B2, MC2R DRD1 2910/4885ALDH1A1 1813/4885POLB 4234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.